Chimeric Therapeutics Ltd. (AU:CHM)
ASX:CHM
Want to see AU:CHM full AI Analyst Report?
CHM Stock Chart & Stats
AU$0.13
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.13
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.07 - AU$0.24
Previous CloseN/A
Volume2.58M
Average Volume (3M)3.63M
Market Cap
AU$3.56M
Enterprise ValueAU$492.52K
Total Cash (Recent Filing)AU$2.50M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding54,728,065
10 Day Avg. Volume3,014,500
30 Day Avg. Volume3,625,345
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.74
Price to Sales (P/S)1.36
P/FCF Ratio-0.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)AU$379.22M
Bulls Say, Bears Say
Bulls Say
FDA Orphan Drug DesignationThe FDA Orphan Drug Designation provides market exclusivity and tax incentives, strengthening Chimeric's competitive position in cancer therapy.
Promising Clinical Trial ResultsPromising trial results enhance Chimeric's reputation and potential for successful therapies, supporting long-term growth in the oncology market.
R&D Tax IncentiveThe R&D tax incentive boosts financial resources for innovation, aiding Chimeric's development of new therapies and reinforcing its market position.
Bears Say
Ongoing Cash BurnContinued cash burn indicates reliance on external funding, which could lead to dilution and financial instability if not addressed.
Shrinking Equity BaseA reduced equity base limits financial flexibility and increases funding risks, potentially affecting Chimeric's ability to sustain operations.
Material Capital RaisingWhile raising capital strengthens finances, it risks significant shareholder dilution, impacting investor returns and market perception.
Chimeric Therapeutics Ltd. News
CHM FAQ
What was Chimeric Therapeutics Ltd.’s price range in the past 12 months?
Chimeric Therapeutics Ltd. lowest share price was AU$0.07 and its highest was AU$0.24 in the past 12 months.
What is Chimeric Therapeutics Ltd.’s market cap?
Chimeric Therapeutics Ltd.’s market cap is AU$3.56M.
When is Chimeric Therapeutics Ltd.’s upcoming earnings report date?
Chimeric Therapeutics Ltd.’s upcoming earnings report date is Aug 28, 2026 which is in 68 days.
How were Chimeric Therapeutics Ltd.’s earnings last quarter?
Chimeric Therapeutics Ltd. released its earnings results on Feb 27, 2026. The company reported -AU$0.344 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.344.
Is Chimeric Therapeutics Ltd. overvalued?
According to Wall Street analysts Chimeric Therapeutics Ltd.’s price is currently Overvalued.
Does Chimeric Therapeutics Ltd. pay dividends?
Chimeric Therapeutics Ltd. does not currently pay dividends.
What is Chimeric Therapeutics Ltd.’s EPS estimate?
Chimeric Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Chimeric Therapeutics Ltd. have?
Chimeric Therapeutics Ltd. has 54,728,065 shares outstanding.
What happened to Chimeric Therapeutics Ltd.’s price movement after its last earnings report?
Chimeric Therapeutics Ltd. reported an EPS of -AU$0.344 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.303%.
Which hedge fund is a major shareholder of Chimeric Therapeutics Ltd.?
Currently, no hedge funds are holding shares in AU:CHM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Chimeric Therapeutics Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
2844.96%
Trailing 12-Months
Asset Growth
-68.25%
Trailing 12-Months
Company Description
Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical firm dedicated to developing and commercializing a diverse array of cell therapies designed to combat various cancers. Its lead natural killer (NK) cell platform, CHM 0201, is currently undergoing Phase I clinical evaluation for both solid tumors and hematological malignancies. Another key candidate, CHM 1101 (a CLTX CAR T therapy), is also in Phase I trials, specifically targeting recurrent or progressive glioblastoma in patients expressing MMP2+. Beyond these, the company's development pipeline encompasses CHM 0301 for blood cancers; CLTX CAR NK (CHM 1301) and CDH17 CAR NK (CHM 2301) for solid tumors. The CLTX CAR T platform (CHM 1101) is additionally being investigated for melanoma, colorectal, and prostate cancers, while CDH17 CAR T (CHM 2101) is being developed for neuroendocrine, colorectal, pancreatic, and gastric cancers. Chimeric Therapeutics, headquartered in Carlton, Australia, was founded in 2020.
Technical Analysis
Prescient Therapeutics Limited
―
Invex Therapeutics Ltd.
―
Noxopharm Ltd.
―
Recce Pharmaceuticals Ltd.
―
Arovella Therapeutics Limited
―
Options Prices
Currently, No data available
---